Glycine site agonists of the N-methyl-D-aspartate receptor and Parkinson's disease: a hypothesis.
Identifieur interne : 000971 ( Main/Exploration ); précédent : 000970; suivant : 000972Glycine site agonists of the N-methyl-D-aspartate receptor and Parkinson's disease: a hypothesis.
Auteurs : Uriel Heresco-Levy [Israël] ; Shai Shoham ; Daniel C. JavittSource :
- Movement disorders : official journal of the Movement Disorder Society [ 1531-8257 ] ; 2013.
English descriptors
- KwdEn :
- MESH :
- chemical , agonists : Receptors, N-Methyl-D-Aspartate.
- chemical , antagonists & inhibitors : Glycine.
- metabolism : Parkinson Disease, Receptors, N-Methyl-D-Aspartate, Schizophrenia.
- Animals, Clinical Trials as Topic, Disease Models, Animal, Humans.
Abstract
Limitations of current pharmacological approaches to Parkinson's disease (PD) highlight the need for the development of nondopaminergic therapeutic strategies. The potential role of glutamatergic neurotransmission modulators, including those active at the N-methyl-D-aspartate receptor (NMDAR), is presently under investigation. Most literature proposes the use of NMDAR antagonists based on neurodegenerative theories of NMDAR function. Nevertheless, NMDAR antagonism has proven disappointing in clinical trials and may be associated with serious adverse events. More recent theories indicate that NMDAR target selectivity may be a cardinal prerequisite for efficacy, with present efforts being devoted primarily to development of NMDAR-NR2B subunit antagonists. We propose a novel hypothesis according to which NMDAR stimulation, accomplished through allosteric modulation via the glycine modulatory site, may be beneficial in late-phase PD. This hypothesis stems from: (1) meta-analysis of randomized controlled trials performed in schizophrenia, indicating that glycine site agonists (eg, glycine, D-serine) alleviate antipsychotic-induced parkinsonian symptoms; (2) clinical observations indicating that NMDAR hypofunction is associated with motor disturbances; (3) results of a preliminary D-serine trial in PD; (4) data indicating glycine efficacy in a rat tardive dyskinesia model; and (5) no evidence of excitotoxic damage following chronic high-dose glycine nutritional supplementation. This hypothesis is discussed in the context of glycine site agonist effects on intrasynaptic NMDAR subunits and striatal synaptic plasticity.
DOI: 10.1002/mds.25306
PubMed: 23427107
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 000A33
- to stream PubMed, to step Curation: 000A33
- to stream PubMed, to step Checkpoint: 000985
- to stream Ncbi, to step Merge: 003A48
- to stream Ncbi, to step Curation: 003A48
- to stream Ncbi, to step Checkpoint: 003A48
- to stream Main, to step Merge: 000971
- to stream Main, to step Curation: 000971
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Glycine site agonists of the N-methyl-D-aspartate receptor and Parkinson's disease: a hypothesis.</title><author><name sortKey="Heresco Levy, Uriel" sort="Heresco Levy, Uriel" uniqKey="Heresco Levy U" first="Uriel" last="Heresco-Levy">Uriel Heresco-Levy</name><affiliation wicri:level="1"><nlm:affiliation>Psychiatry Department, Ezrath Nashim-Herzog Memorial Hospital and Hebrew University Hadassah Medical School, Jerusalem, Israel. heresco@md.huji.ac.il</nlm:affiliation><country xml:lang="fr">Israël</country><wicri:regionArea>Psychiatry Department, Ezrath Nashim-Herzog Memorial Hospital and Hebrew University Hadassah Medical School, Jerusalem</wicri:regionArea><wicri:noRegion>Jerusalem</wicri:noRegion></affiliation></author><author><name sortKey="Shoham, Shai" sort="Shoham, Shai" uniqKey="Shoham S" first="Shai" last="Shoham">Shai Shoham</name></author><author><name sortKey="Javitt, Daniel C" sort="Javitt, Daniel C" uniqKey="Javitt D" first="Daniel C" last="Javitt">Daniel C. Javitt</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2013">2013</date><idno type="doi">10.1002/mds.25306</idno><idno type="RBID">pubmed:23427107</idno><idno type="pmid">23427107</idno><idno type="wicri:Area/PubMed/Corpus">000A33</idno><idno type="wicri:Area/PubMed/Curation">000A33</idno><idno type="wicri:Area/PubMed/Checkpoint">000985</idno><idno type="wicri:Area/Ncbi/Merge">003A48</idno><idno type="wicri:Area/Ncbi/Curation">003A48</idno><idno type="wicri:Area/Ncbi/Checkpoint">003A48</idno><idno type="wicri:Area/Main/Merge">000971</idno><idno type="wicri:Area/Main/Curation">000971</idno><idno type="wicri:Area/Main/Exploration">000971</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Glycine site agonists of the N-methyl-D-aspartate receptor and Parkinson's disease: a hypothesis.</title><author><name sortKey="Heresco Levy, Uriel" sort="Heresco Levy, Uriel" uniqKey="Heresco Levy U" first="Uriel" last="Heresco-Levy">Uriel Heresco-Levy</name><affiliation wicri:level="1"><nlm:affiliation>Psychiatry Department, Ezrath Nashim-Herzog Memorial Hospital and Hebrew University Hadassah Medical School, Jerusalem, Israel. heresco@md.huji.ac.il</nlm:affiliation><country xml:lang="fr">Israël</country><wicri:regionArea>Psychiatry Department, Ezrath Nashim-Herzog Memorial Hospital and Hebrew University Hadassah Medical School, Jerusalem</wicri:regionArea><wicri:noRegion>Jerusalem</wicri:noRegion></affiliation></author><author><name sortKey="Shoham, Shai" sort="Shoham, Shai" uniqKey="Shoham S" first="Shai" last="Shoham">Shai Shoham</name></author><author><name sortKey="Javitt, Daniel C" sort="Javitt, Daniel C" uniqKey="Javitt D" first="Daniel C" last="Javitt">Daniel C. Javitt</name></author></analytic><series><title level="j">Movement disorders : official journal of the Movement Disorder Society</title><idno type="eISSN">1531-8257</idno><imprint><date when="2013" type="published">2013</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term><term>Clinical Trials as Topic</term><term>Disease Models, Animal</term><term>Glycine (antagonists & inhibitors)</term><term>Humans</term><term>Parkinson Disease (metabolism)</term><term>Receptors, N-Methyl-D-Aspartate (agonists)</term><term>Receptors, N-Methyl-D-Aspartate (metabolism)</term><term>Schizophrenia (metabolism)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="agonists" xml:lang="en"><term>Receptors, N-Methyl-D-Aspartate</term></keywords><keywords scheme="MESH" type="chemical" qualifier="antagonists & inhibitors" xml:lang="en"><term>Glycine</term></keywords><keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>Parkinson Disease</term><term>Receptors, N-Methyl-D-Aspartate</term><term>Schizophrenia</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Clinical Trials as Topic</term><term>Disease Models, Animal</term><term>Humans</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Limitations of current pharmacological approaches to Parkinson's disease (PD) highlight the need for the development of nondopaminergic therapeutic strategies. The potential role of glutamatergic neurotransmission modulators, including those active at the N-methyl-D-aspartate receptor (NMDAR), is presently under investigation. Most literature proposes the use of NMDAR antagonists based on neurodegenerative theories of NMDAR function. Nevertheless, NMDAR antagonism has proven disappointing in clinical trials and may be associated with serious adverse events. More recent theories indicate that NMDAR target selectivity may be a cardinal prerequisite for efficacy, with present efforts being devoted primarily to development of NMDAR-NR2B subunit antagonists. We propose a novel hypothesis according to which NMDAR stimulation, accomplished through allosteric modulation via the glycine modulatory site, may be beneficial in late-phase PD. This hypothesis stems from: (1) meta-analysis of randomized controlled trials performed in schizophrenia, indicating that glycine site agonists (eg, glycine, D-serine) alleviate antipsychotic-induced parkinsonian symptoms; (2) clinical observations indicating that NMDAR hypofunction is associated with motor disturbances; (3) results of a preliminary D-serine trial in PD; (4) data indicating glycine efficacy in a rat tardive dyskinesia model; and (5) no evidence of excitotoxic damage following chronic high-dose glycine nutritional supplementation. This hypothesis is discussed in the context of glycine site agonist effects on intrasynaptic NMDAR subunits and striatal synaptic plasticity.</div></front></TEI><affiliations><list><country><li>Israël</li></country></list><tree><noCountry><name sortKey="Javitt, Daniel C" sort="Javitt, Daniel C" uniqKey="Javitt D" first="Daniel C" last="Javitt">Daniel C. Javitt</name><name sortKey="Shoham, Shai" sort="Shoham, Shai" uniqKey="Shoham S" first="Shai" last="Shoham">Shai Shoham</name></noCountry><country name="Israël"><noRegion><name sortKey="Heresco Levy, Uriel" sort="Heresco Levy, Uriel" uniqKey="Heresco Levy U" first="Uriel" last="Heresco-Levy">Uriel Heresco-Levy</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000971 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000971 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:23427107
|texte= Glycine site agonists of the N-methyl-D-aspartate receptor and Parkinson's disease: a hypothesis.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:23427107" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a MovDisordV3
| This area was generated with Dilib version V0.6.23. |  |